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A B S T R A C T   
The coronavirus disease 2019 (COVID-19) pandemic highlights the importance of strong and resilient health 
systems. Yet how much a society should spend on healthcare is difficult to determine because additional health 
expenditures imply lower expenditures on other types of consumption. Furthermore, the welfare-maximizing 
(“efficient”) aggregate amount and composition of health expenditures depend on efficiency concepts at three 
levels that often get blurred in the debate. While the understanding of efficiency is good at the micro- and meso- 
levels—that is, relating to minimal spending for a given bundle of treatments and to the optimal mix of different 
treatments, respectively—this understanding rarely links to the efficiency of aggregate health expenditure at the 
macroeconomic level. While micro- and meso-efficiency are necessary for macro-efficiency, they are not suffi-
cient. We propose a novel framework of a macro-efficiency score to assess welfare-maximizing aggregate health 
expenditure. This allows us to assess the extent to which selected major economies underspend or overspend on 
health relative to their gross domestic products per capita. We find that all economies under consideration 
underspend on healthcare with the exception of the United States. Underspending is particularly severe in China, 
India, and the Russian Federation. Our study emphasizes that the major and urgent issue in many countries is 
underspending on health at the macroeconomic level, rather than containing costs at the microeconomic level.   
1. Introduction 
To tackle health emergencies, such as the coronavirus disease 2019 
(COVID-19) pandemic, and to cope with the health-related challenges of 
the unprecedented population aging that the world currently faces 
(Bloom et al., 2015, 2018, 2020; Chen and Bloom, 2019; Chen et al., 
2018, 2019b), nations need strong and resilient health systems. Coun-
tries’ health expenditures increased strongly in recent decades, not just 
in absolute terms but also as shares of their gross domestic products 
(GDPs) (Papanicolas et al., 2018). This increase in global health 
expenditure is expected to continue over the coming years and to reach 
more than US$24 trillion by 2040 (Dieleman et al., 2017). Yet the 
important question of whether such high spending levels are optimal 
remains largely unanswered. While one analysis suggests that the 
spending level for the United States may be too low (Hall and Jones, 
2007), this result remains up for debate (Cutler, 2021) and systematic 
and rigorous investigations of other countries are scarce. 
Facing growing health expenditures, many researchers question the 
efficiency of the healthcare sector. Previous studies suggest that in-
efficiencies exist in the production, organization, and administration of 
healthcare; in the allocation of health expenditure across services and 
sub-groups of the population; and in the adoption of new technologies 
(Baicker et al., 2012; Berwick and Hackbarth, 2012; Chandra and 
Skinner, 2012; Chandra and Staiger, 2020; Cutler, 2018; Cutler and Ly, 
2011; Garber and Skinner, 2008). However, these studies mainly focus 
on micro-level (or production) efficiency, i.e. the production of a given 
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volume and type of healthcare using minimal inputs, or on meso-level 
(or allocative) efficiency in the sense of a welfare-maximizing mix of 
healthcare services for a given aggregate healthcare budget (Jacobs 
et al., 2006; World Health Organization, 2016). Few studies have 
explored the macro-level efficiency of health expenditure in the sense of 
a welfare-maximizing mix of aggregate health expenditure and spending 
on other goods and services (consumption in particular). 
Exploring macro-level efficiency of health expenditure is crucial for 
policymaking. Decisions based solely on the micro-level and meso-level 
efficiency of health expenditure may lead to the wide implementation of 
cost-containment strategies such as regulating drug prices, lowering 
costs in public hospitals, and setting spending caps for healthcare ser-
vices (Busse and Blümel, 2014; Busse et al., 2017; Busse et al., 2013; 
Garber et al., 2007; Li, 2011; Liu et al., 2017; Liu et al., 2019; Mossialos 
and Le Grand, 2019; Stabile et al., 2013; Stadhouders et al., 2019; Yip 
et al., 2019) that could be counterproductive from an aggregate 
perspective. This is because, at the aggregate level, the share of health 
expenditure in GDP may be inefficiently low and cost-containment 
strategies may exacerbate this problem, inter alia, by impeding quality 
and innovation in healthcare. To understand why, it is important to 
recognize that two fundamentally different factors drive high and 
growing health expenditure shares. These factors are (i) overspending 
due to inefficiency in the production and allocation of healthcare and (ii) 
a high demand for efficiently provided healthcare that grows even 
further in times of population aging. Separating efficient from inefficient 
spending increases is challenging both conceptually and practically. 
In this article we focus on the macroeconomic efficiency of health 
expenditure, i.e., whether countries underspend or overspend on 
healthcare relative to all other types of consumption. We provide a novel 
and simple way to test for macro-efficiency and determine the extent to 
which the following important large economies—Argentina, Australia, 
Brazil, Canada, China, France, Germany, India, Italy, Japan, the Russian 
Federation, South Africa, Spain, the United Kingdom, and the United 
States—underspend or overspend on health at the macro level. 
2. Methodology 
2.1. Data sources 
To perform the test for 15 large economies, we rely on World 
Development Indicators (2021) data on life expectancy, consumption 
expenditures as a share of GDP, health expenditures as a share of GDP, 
and GDP itself (World Bank, 2021). In the main analysis, we use data for 
2015 and, in further analysis, we also use 2010 data to show how the 
macro-efficiency score changed over time. As a specification for 
instantaneous utility, we apply a standard isoelastic utility function. As 
the inverse of the elasticity of intertemporal substitution, i.e., a measure 
of how willing households are to sacrifice consumption today in ex-
change for consumption tomorrow, we use the value 1.01, which is well 
in line with empirical evidence (Chetty, 2006). In addition, we consider 
that individuals discount their future utility at a rate of 2.5 % (Kuhn and 
Prettner, 2016). The main text provides details of our estimation of the 
elasticity of longevity with respect to health expenditure (henceforth 
“longevity elasticity”), while the Appendix provides a detailed descrip-
tion of the parameter values and data sources used in the simulations. 
2.2. Model structure 
Based on previous research (Hall and Jones, 2007), we derive from a 
simple model a macro-efficiency score that indicates whether an econ-
omy underspends or overspends on healthcare (see the Appendix for a 
full derivation). We assume individuals maximize their discounted 
lifetime utility u(c)⋅DLE(h), as defined by the utility u(c) from annual 
consumption c multiplied by the individual’s discounted life expectancy 
at birth DLE(h), which can be increased by annual health expenditure h. 
Note that DLE(h) is a measure (for a precise formulation, see the Ap-
pendix) that increases with life expectancy at birth LE(h) and decreases 
with the rate of time preference at which individuals discount the future 
(i.e., the extent to which they prefer present day consumption). 
Individuals allocate their income to consumption, which raises their 
utility within each life year, and health investments, which increase life 
expectancy and allow the spread of consumption utility over additional 
life years, according to the budget constraint y = c+ h. We show in the 
Appendix that this yields an optimal spending rule, according to which 
the ratio of health expenditures to consumption expenditures equals the 
ratio of the elasticity of discounted life expectancy with respect to health 
expenditure (henceforth “discounted longevity elasticity”), DLE
′
(h)⋅h
DLE(h) , and 












where DLE′ (h) and u′ (c) denote the marginal effects of health care on 
the discounted life expectancy at birth and on period utility, respec-
tively. The elasticities are defined as the percentage change in dis-
counted longevity and utility for a 1 % increase in health and 
consumption expenditures, respectively. Thus, they measure the effec-
tiveness of health expenditure versus consumption in raising life-cycle 
utility. 
The optimal spending rule yields the following insights: (i) A richer 
country would, all else equal, spend more on healthcare relative to 
consumption. This follows from the fact that a lower elasticity of con-
sumption utility typically characterizes rich countries, reflecting the 
decreasing effects of additional consumption on utility that follows from 
the hierarchy of individual needs. For a given discounted longevity 
elasticity, a rich country is thus willing to devote a greater share of in-
come to healthcare. (ii) It can be shown (see the Appendix) that the 
discounted longevity elasticity decreases with the level of life expec-
tancy and with the discount rate. Intuitively, countries with lower levels 
of life expectancy and with more patient populations tend to value more 
an increase in longevity. (iii) Medical progress that raises the discounted 
longevity elasticity triggers a reallocation of available income from 
consumption to healthcare. (iv) Countries that for some reason are less 
effective in producing health, as measured by a lower discounted 
longevity elasticity, should, all else equal, spend less on healthcare. 
While many exogenous factors—such as demographic, social, cultural, 
and environmental determinants of health—may explain why countries 
differ in the productivity of their health expenditure, an intricate link 
exists between production efficiency and macroeconomic efficiency. 
Suppose two countries, A and B, share the same level of per capita 
GDP, but country B runs an inefficient health system and therefore ex-
hibits a lower longevity elasticity. In this case, according to the optimal 
spending rule, country B should devote fewer resources to healthcare. 
While redirecting resources away from a relatively inefficient use can be 
viewed as a “locally” optimal response, it would be misguided in global 
terms. The appropriate strategy would be to reorganize the health sys-
tem toward improved efficiency and maintain (or, depending on the 
starting point, increase) overall health expenditure. Hence, whether 
“cost containment” reflects warranted efficiency gains or whether it 
reflects unwarranted spending cuts must be considered very carefully. 
In reality, the optimal spending rule may not be met for the following 
reasons: (i) lacking expert knowledge, individuals typically delegate 
most of their healthcare choices to physicians who, following their own 
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objectives, may spend non-optimally (Arrow, 1963); (ii) where in-
dividuals determine spending levels, lack of information about treat-
ment effectiveness may lead to suboptimal spending decisions; and (iii) 
where the government and insurance firms determine spending levels, 
they may follow spending rules that are unrelated to the individual’s 
optimization. For instance, evidence exists that government spending in 
the United States reflects special interests rather than the median voter’s 
preferences (Gilens and Page, 2014; Page et al., 2013). 
To assess the extent of underspending or overspending, we transform 
the optimal spending rule into a macro-efficiency score (Appendix, 
equation (2)). Underspending on healthcare prevails if the macro- 
efficiency score is less than 1, and the reverse holds true if the score 
exceeds 1. By setting the macro-efficiency score equal to 1, we can 
recalculate optimal health expenditures and, thus, the percentage gap 
between actual and optimal expenditures. 
2.3. Output estimates 
We calculate the macro-efficiency score for the following coun-
tries—Argentina, Australia, Brazil, Canada, China, France, Germany, 
India, Italy, Japan, the Russian Federation, South Africa, Spain, the 
United Kingdom, and the United States—to assess how much these 
countries underspend or overspend relative to their GDP per capita. 
Recalling that the utility elasticity with respect to consumption tends 
to fall with increasing consumption and, by implication, with increasing 
GDP per capita, determining the longevity elasticity is the only aspect 
that remains undone. Unfortunately, we lack country-specific data on 
this elasticity. To obtain an “average” measure, we use data from the 
World Development Indicators (World Bank, 2021) to regress the log of 
life expectancy on the log of health expenditures, controlling for the log 
of per capita income, the share of people aged 65 and older, and the 
squared terms of the log of per capita income and the share of people 
above the age of 65. The inclusion of squared terms accounts for non-
linearities in the relationship. For countries with a GDP per capita higher 
than the global median, we obtain an estimate for the longevity elas-
ticity of 0.051 for the year 2015, implying that a 1 % increase in health 
expenditure raises life expectancy by 0.051 %. We then use this 
longevity elasticity to calculate the macro-efficiency score. We also 
derive the optimal health expenditure for each country. To provide 
changes across time, we further compute the macro-efficiency score for 
the year 2010 using the longevity elasticity of 0.061 estimated for the 
year 2010. The Appendix provides further detail on parameter choices 
and data sources. 
2.4. Validity check based on the value of a statistical life 
One advantage of our approach is that it allows for computing an 
implied value of a statistical life (VSL) across countries that we can 
compare to the estimated value in a country, derived from the literature 
(Viscusi and Masterman, 2017). Doing so represents an independent 
validity check of our results on the extent of underspending or over-
spending on healthcare. See the Appendix for further details on the VSL 
calculations. 
2.5. Sensitivity analysis 
Furthermore, we conduct a sensitivity analysis using the longevity 
elasticity of 0.04, as found in a meta-analysis of different estimates 
(Gallet and Doucouliagos, 2017). 
3. Results 
3.1. Macro-efficiency score and the assessment of underspending or 
overspending on health 
Table 1 presents the macro-efficiency scores that indicate whether a 
country underspends or overspends on healthcare. In 2015, Canada and 
Japan spent around 10 % of their respective GDPs on healthcare; the 
United States exhibited considerably higher spending of close to 17 %, 
whereas China, India, and the Russian Federation spent only around 4 % 
to 5 % of their GDPs on health. Judging from the macro-efficiency 
scores, all countries under consideration underinvest in healthcare 
except the United States. While the United States underspent in 2010, it 
overspent in 2015, indicating that the current health expenditure share 
in GDP for the United States is likely to be near the optimal point. On the 
other side of the range, underinvestment is particularly pronounced in 
China, India, and the Russian Federation. 
3.2. The gap between current and optimal health expenditure in GDP 
Figure 1 shows the gap between current and optimal health expen-
diture in GDP for each country in 2015. The countries are ranked by the 
gap between current and optimal health expenditure in GDP, which is 
largest in India (67.4 %), followed by the Russian Federation (65.9 %), 
China (63.8 %), and South Africa (47.9 %). In contrast, the United States 
overspent by 4.3 %. 
Table 1 
Macro-efficiency score and health expenditure (% of GDP) in 2010 and 2015.  
Country 2010 2015 
Macro-efficiency score Health expenditure (% of GDP) Macro-efficiency score Health expenditure (% of GDP) 
Argentina 0.49 9.45 0.54 8.79 
Australia 0.43 8.43 0.57 9.31 
Brazil 0.42 7.95 0.57 8.87 
Canada 0.55 10.68 0.65 10.51 
China 0.25 4.21 0.33 4.89 
France 0.59 11.24 0.73 11.46 
Germany 0.57 11.10 0.68 11.09 
India 0.18 3.27 0.24 3.60 
Italy 0.46 8.92 0.56 8.99 
Japan 0.48 9.16 0.70 10.89 
Russian Federation 0.23 4.97 0.30 5.30 
South Africa 0.34 7.42 0.48 8.20 
Spain 0.47 9.12 0.57 9.11 
United Kingdom 0.51 9.99 0.59 9.69 
United States 0.85 16.35 1.05 16.84 
Note: The longevity elasticity is 0.061 and 0.051 for 2010 and 2015, respectively, and is based on our estimates using World Bank data. A macro-efficiency score in 
excess of 1 indicates overspending, while a score below 1 indicates underspending on healthcare. Health expenditure (% of GDP) is based on World Bank data. 
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3.3. Validity check based on the value of a statistical life 
Table 2 calculates for our model the VSL as a measure of how much 
individuals would be willing to pay for an instantaneous reduction in 
mortality (Hall and Jones, 2007; Murphy and Topel, 2006) and com-
pares it with the micro-econometric estimates of Viscusi and Masterman 
(2017). Although the VSL values are derived by very different methods, 
they are of the same order of magnitude, underscoring the validity of our 
computations. 
3.4. Sensitivity analysis 
We then conducted a sensitivity analysis using the lower longevity 
elasticity estimate of 0.04, taken from a recent meta-analysis (Gallet and 
Doucouliagos, 2017). The results remain robust, with India, the Russian 
Federation, and China having the lowest and the United States having 
the highest macro-efficiency scores (see Table 3). All countries except 
for the United States underspend on health. 
4. Discussion 
4.1. Underspending on healthcare 
This study, for the first time, estimates the macro-level efficiency of 
health expenditure for 15 countries. We find that from a macroeconomic 
perspective, almost all countries included in our analysis would benefit 
from increasing their health expenditure. Despite their relatively high 
health expenditure shares, countries such as Argentina, Australia, Can-
ada, Italy, Japan, and the United Kingdom would benefit from further 
expansion, as the high GDP levels in these countries translate into large 
VSLs. Underinvestment is particularly pronounced in China, India, and 
the Russian Federation due to the low share of health expenditures in 
GDP, which might be due to these countries following other priorities in 
spending, such as on infrastructure in the case of China (Chen et al., 
2020). 
In general, the optimal shares of health expenditure in GDP are 
similar across countries, ranging between 14 % in China and India to 16 
% in the United States. Although the lower GDP and associated VSL in 
China and India imply a lower optimal share of health expenditures in 
GDP, our macro-efficiency score indicates that the current spending 
shares are so low that these two countries would particularly benefit 
from spending increases. The situation is somewhat different for the 
Figure 1. Current and optimal health expenditure shares (% of GDP). Note: The countries are sorted based on the percentage gap between the current versus optimal 
health expenditure share in GDP. The current health expenditure (% of GDP) is based on World Bank data from 2015. The optimal health expenditure (% of GDP) is 
estimated from our framework using the longevity elasticity of 0.051. 
Table 2 
Comparison between VSL estimates (in million USD).  
Country VSL (model) VSL (estimated) 
2010 2015 
Argentina 3.99 4.20 2.14 
Australia 7.27 7.96 10.34 
Brazil 2.21 2.41 1.70 
Canada 7.36 7.99 8.18 
China 0.66 1.11 1.36 
France 6.65 6.71 6.98 
Germany 7.40 7.78 7.90 
India 0.47 0.68 0.28 
Italy 7.48 7.04 5.65 
Japan 6.17 6.40 6.68 
Russian Federation 3.09 3.44 1.97 
South Africa 1.62 1.75 1.05 
Spain 6.13 6.21 4.91 
United Kingdom 7.77 8.39 7.47 
United States 10.85 11.68 9.63 
Note: The longevity elasticity is 0.061 and 0.051 for 2010 and 2015, respec-
tively, and is based on our estimates using World Bank data. The VSL (model) is 
calculated within our framework, while the VSL (estimated) is from Viscusi and 
Masterman (2017). 
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Russian Federation and for South Africa, with both countries exhibiting 
optimal shares of health expenditures in GDP that are comparable to or 
even exceed those of countries with higher GDPs per capita. Here the 
reason lies in the low levels of life expectancy, which tend to support a 
higher optimal share of health expenditures in GDP. Generally, given the 
longevity elasticity, the optimal health expenditure share in GDP is 
explained by both GDP per capita (particularly low in China and India; 
particularly high in the United States) pointing at a higher spending 
share and life expectancy (particularly low in the Russian Federation, 
South Africa, and India; particularly high in Japan) pointing at a lower 
spending share. 
Overall, the United States is the only country exhibiting over-
spending, particularly in 2015. The explanation for this is rooted in the 
relatively high share of health expenditure in GDP. To decidedly answer 
the question raised by Garber and Skinner (2008), “Is American 
healthcare uniquely inefficient?” we would, however, require more 
precise estimates of the longevity elasticity for the United States. 
Our study emphasizes that the major and urgent issue in many 
countries is underinvestment in health at the macroeconomic level, 
rather than containing costs at the microeconomic level. Countries 
should further expand their healthcare sectors by increasing investment 
and promoting innovation of high-quality and effective care that can 
increase longevity. While such an expansion should be executed in a way 
that is micro-efficient, our analysis shows that an exclusive focus on 
expenditure containment is inappropriate. Health expenditure should 
not be viewed simply as a burden; rather, it is a reflection of countries’ 
modernization and respect for their citizens, whose wellbeing depends 
decisively on living long and healthy lives. 
4.2. Valuing health at the macroeconomic level 
Our result that most countries included in our analysis underspend 
on healthcare is based on a relatively narrow macro-efficiency criterion 
relating to income and the effectiveness of healthcare in raising life 
expectancy. We would expect an even stronger case for investments in 
health and healthcare within a broader macroeconomic framework. 
First, investments in health and healthcare can drive economic 
growth by improving population health. Healthier populations tend to 
have higher labor force participation rates, greater productivity, and 
longer working lifespans (Bloom and Canning, 2000; Bloom et al., 
2019a; Bloom et al., 2020; Bloom et al., 2019b; Bloom et al., 2018; 
Bloom et al., 2019c; Chen and Bloom, 2019; Chen et al., 2018; Chen 
et al., 2019a, b; Weil, 2007). With more of the population in employ-
ment and a higher production potential for each worker, a country with 
a healthier population can achieve higher per capita output. Longer life 
expectancy also incentivizes savings, education, and investment in 
research and development (R&D), which in turn contribute to economic 
growth (Ben-Porath, 1967; Bloom and Canning, 2000; Bloom et al., 
2003; Cervellati & Sunde, 2005, 2013, 2013; Gehringer and Prettner, 
2019; Prettner and Trimborn, 2017). These dynamic effects are, at best, 
incompletely reflected in the individual’s willingness to pay for 
healthcare and, thus, tend to imply that our macro-efficiency score is 
prone to underestimate the spending level required to attain macro-
economic efficiency in an economic growth context. 
Second, medical and healthcare services can also drive economic 
growth through technological innovation. Studies show that, as the size 
and value of the healthcare market increases, the extent of R&D activity 
on pharmaceuticals and advanced medical technology and their diffu-
sion expands (Acemoglu and Linn, 2004; Clemens, 2013; Finkelstein, 
2004, 2007, 2007; Frankovic and Kuhn, 2018; Frankovic et al., 2020). 
Large welfare gains can also be achieved even if many of the ensuing 
innovations are not cost-effective (Böhm et al., 2021; Chandra and 
Skinner, 2012; Fonseca et al., 2020; Frankovic and Kuhn, 2018; Frank-
ovic et al., 2020), which follows as a corollary to our finding that income 
growth should increasingly translate into health expenditure. Notably, 
this case is weakened to the extent that medical spending is subject to 
decreasing returns, leading to “flat-of-the-curve” medicine. Medical 
progress is then valuable in shifting the whole health production func-
tion upward, affording an increase in medical productivity throughout. 
Jones (2016) shows that under plausible assumptions about preferences, 
this is true even if medical R&D crowds out innovations aimed at con-
ventional productivity growth. 
Third, investments in health and healthcare can also improve the 
quality and resilience of health systems, which can ensure social sta-
bility, especially in an emergency. A modern health system with a 
certain excess capacity in terms of equipment, beds, and staff can be 
viewed as a form of insurance against large-sized medical incidents, such 
as accidents involving mass casualties, natural or manmade disasters, 
and epidemic outbreaks of infectious diseases (Attema et al., 2010; 
Lakdawalla et al., 2017; Megiddo et al., 2019; Philipson and Zanjani, 
2014; Zweifel et al., 2009; Chen et al., 2020a, 2020b). In today’s 
interconnected world, emerging infectious diseases with pandemic po-
tential can cost millions of lives, cause economic upheaval, and disrupt 
travel and trade (Acemoglu et al., 2020; Eichenbaum et al., 2020; Glover 
et al., 2020; International Monetary Fund; International Monetary Fund, 
2020; Krueger et al., 2020; U.S. Department of Health and Human 
Services, 2010; Chen et al., 2020, 2021a,b). Developing modern health 
systems, advanced medical and healthcare technology, and sufficient 
Table 3 
Macro-efficiency score and health expenditure (% of GDP) in 2010 and 2015 using a longevity elasticity estimate of 0.04 (Gallet and Doucouliagos, 2017).  
Country 2010 2015 
Macro-efficiency score Health expenditure (% of GDP) Macro-efficiency score Health expenditure (% of GDP) 
Argentina 0.74 9.45 0.69 8.79 
Australia 0.66 8.43 0.73 9.31 
Brazil 0.64 7.95 0.73 8.87 
Canada 0.85 10.68 0.83 10.51 
China 0.38 4.21 0.42 4.89 
France 0.91 11.24 0.93 11.46 
Germany 0.87 11.10 0.88 11.09 
India 0.28 3.27 0.30 3.60 
Italy 0.70 8.92 0.71 8.99 
Japan 0.74 9.16 0.90 10.89 
Russian Federation 0.36 4.97 0.39 5.30 
South Africa 0.53 7.42 0.61 8.20 
Spain 0.73 9.12 0.73 9.11 
United Kingdom 0.78 9.99 0.75 9.69 
United States 1.31 16.35 1.35 16.84 
Note: The longevity elasticity of 0.04 is estimated within a meta-regression consisting of 65 studies completed over the 1969–2014 period (Gallet and Doucouliagos, 
2017). A macro-efficiency score in excess of 1 indicates overspending, while a score below 1 indicates underspending on healthcare. Health expenditure (% of GDP) is 
based on World Bank data. 
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capacity in terms of facilities, equipment, and trained staff are crucial to 
ensure not only health system stability, but social and economic stability 
as well. 
4.3. Strengths 
Against a large body of evidence on the productive efficiency of 
healthcare in various settings, this study is the first to provide an intu-
itive yet rigorous test for the macroeconomic efficiency of health 
expenditure. One strength is that we derive the macro-efficiency score 
from economic theory. A second strength is that the macro-efficiency 
score can be calculated based on relatively easily accessible data, 
although the test can, in principle, be extended to more complex settings 
and/or detailed data. Our approach allows for a straightforward 
assessment and ranking of the extent to which countries underspend or 
overspend on healthcare. 
4.4. Limitations 
Our analysis has several caveats. First and most important, our test 
only allows us to assess the deviation from a macro-efficient spending 
level that is conditional on average production efficiency, as measured 
by the estimated longevity elasticity. Thus, while our conservative use of 
a lower estimate of the longevity elasticity than the one we estimate 
provides a robust assessment of the direction of macro-inefficiency for 
the countries under consideration, we cannot disentangle macro- 
inefficiency from micro-inefficiency (i.e., production inefficiency) at 
the country level. This implies that the measured macro-inefficiency (i. 
e., the deviation from 1) may to some extent be upward or downward 
biased. 
Second, our results are preconditioned on our use of life expectancy 
at birth as the outcome criterion. While this is consistent with the un-
derlying framework in Hall and Jones (2007), it fails to incorporate 
explicitly quality-of-life dimensions of healthcare. That said, life ex-
pectancy is a plausible (long-run) proxy for health in itself (Vaupel, 
2010), while, in economic terms, quality of life is a close complement to 
length of life in generating utility (Hall and Jones, 2007; Murphy and 
Topel, 2006). Assuming that countries choose a mix of healthcare that 
balances length of life and quality of life, one can then interpret life 
expectancy as a sufficient statistic for quality-related aspects of health as 
well (Chandra and Skinner, 2012). On these grounds, we argue for the 
robustness of our results when it comes to assessing the macro-efficiency 
of healthcare spending. 
Third, our test is based on the assumptions that (i) the social benefits 
of health expenditure equal the private benefit of greater longevity 
(including quality of life for the sake of the argument), while (ii) the 
opportunity cost of health expenditure is appropriately measured by the 
marginal utility of foregone consumption. Both (i) and (ii) require 
qualification, as (i) some interventions such as vaccinations not only 
improve an individual’s private health but also generate positive ex-
ternalities by improving population health, and (ii) the marginal utility 
of foregone consumption appropriately measures the opportunity cost of 
spending only when assuming that other investments chosen by the 
individual follow a similar optimality rule as that outlined in the optimal 
spending rule (Appendix, equation (1)). In particular, this is important 
in the context of spending on education. Extensive evidence exists on the 
complementarity of health and education as components of human 
capital, implying that underinvestment in one domain is associated with 
underinvestment in the other domain as well (Bleakley, 2007, 2010, 
2010; Cervellati & Sunde, 2013, 2015, 2015; Field et al., 2009; Hansen 
and Strulik, 2017; Jayachandran and Lleras-Muney, 2009; Ller-
as-Muney, 2005; Lucas, 2010; Miguel and Kremer, 2004). This suggests 
that our findings are on the conservative side. We provide further 
analysis and discussion in the Appendix. 
Fourth, we cannot easily extend our analysis to low-income coun-
tries. When running the regression for the countries below the median 
world income, the longevity elasticity is insignificant, mainly because 
mortality is determined by many aspects that are not closely related to 
health expenditures in these countries, such as hunger and a lack of 
clean drinking water. Thus, we only include middle- and high-income 
countries in this study. 
We conclude by noting that all of these caveats predominantly relate 
to measurement issues, which the use of more elaborate indicators and/ 
or additional data can address. They do not, however, compromise the 
general design and applicability of our test for macro-efficiency. 
5. Conclusion 
While the understanding of efficiency in health spending is robust at 
the micro- and meso-levels, the efficiency of health expenditure at the 
macroeconomic level is less studied and understood. We developed a 
score to assess the macro-efficiency of health expenditure and found that 
Argentina, Australia, Brazil, Canada, China, France, Germany, India, 
Italy, Japan, the Russian Federation, South Africa, Spain, and the United 
Kingdom all underspend on healthcare and would benefit from devoting 
more resources to their healthcare sectors. The United States is the only 
country exhibiting overspending. Our study emphasizes that the major 
and urgent issue in many countries is underinvestment in health at the 
macroeconomic level, rather than containing costs at the microeco-
nomic level. Health, healthcare, and medical science are essential to a 
citizenry’s welfare and are important for social stability. Health 
expenditure should not be viewed simply as a burden; rather, it is a 
reflection of a country’s modernization and respect for its citizens, 
whose wellbeing depends decisively on living long and healthy lives. 
Looking forward, a high-quality, responsive, and resilient health system 
and an efficient and innovative mechanism to promote R&D in public 
health and medical sciences are urgently needed more than ever. 
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